{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:47Z","timestamp":1793317907683,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejso.2021.10.016","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T08:03:06Z","timestamp":1634889786000},"page":"60-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study"],"prefix":"10.1016","volume":"48","author":[{"given":"R.A.W.","family":"Ploumen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.B.M.I.","family":"Keymeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.S.","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.J.","family":"van Kuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2021.10.016_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jncimonographs\/lgv023","article-title":"International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fifth symposium on primary systemic therapy in the management of operable breast cancer, cremona, Italy (2013)","author":"Amoroso","year":"2015","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejso.2021.10.016_bib2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1245\/s10434-011-2108-2","article-title":"Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer","volume":"19","author":"Kaufmann","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib3","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"16","author":"Fisher","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib4","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2021.10.016_bib5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","article-title":"Pathological complete response in neoadjuvant treatment of breast cancer","volume":"22","author":"Cortazar","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00432-019-03083-y","article-title":"Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis","volume":"146","author":"LeVasseur","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10549-017-4155-2","article-title":"Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients","volume":"163","author":"Goorts","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2021.10.016_bib8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/sj.bjc.6602950","article-title":"Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma","volume":"94","author":"Jones","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2021.10.016_bib10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","article-title":"Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)","volume":"132","author":"von Minckwitz","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2021.10.016_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2021.10.016_bib12","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2021.10.016_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-010-1228-x","article-title":"Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials","volume":"125","author":"von Minckwitz","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2021.10.016_bib14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18","author":"Wolmark","year":"2001","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejso.2021.10.016_bib15","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib16","series-title":"\u2018Treatment of breast cancer\u2019 (Richtlijn \u2018Behandeling van het Mammacarcinoom\u2019)","author":"Guideline","year":"2008"},{"key":"10.1016\/j.ejso.2021.10.016_bib17","series-title":"Treatment of breast cancer","author":"Guideline","year":"2012"},{"key":"10.1016\/j.ejso.2021.10.016_bib18","series-title":"Treatment of breast cancer","author":"Guideline","year":"2017"},{"key":"10.1016\/j.ejso.2021.10.016_bib19","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib20","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1245\/s10434-019-07533-2","article-title":"Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy","volume":"26","author":"Sun","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","article-title":"A\u00a0clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can Be eliminated following neoadjuvant systemic therapy","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2021.10.016_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.annonc.2019.10.012","article-title":"Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges","volume":"31","author":"Heil","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib24","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","article-title":"Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration","volume":"26","author":"Bossuyt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","article-title":"Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study","volume":"158","author":"Doebar","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2021.10.016_bib26","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.bjc.6605655","article-title":"Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer","volume":"102","author":"Wong","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2021.10.016_bib27","first-page":"791","article-title":"Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy","volume":"20","author":"Amat","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","article-title":"Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy","volume":"170","author":"Haque","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2021.10.016_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1245\/s10434-015-4603-3","article-title":"Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer","volume":"23","author":"Truin","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-013-2751-3","article-title":"Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer","volume":"142","author":"Petrelli","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2021.10.016_bib31","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/annonc\/mdl114","article-title":"Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution","volume":"17","author":"Tubiana-Hulin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib32","first-page":"1027","article-title":"The intraductal component of breast cancer is poorly responsive to neo-adjuvant chemotherapy","volume":"9","author":"Wu","year":"2002","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejso.2021.10.016_bib33","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ejso.2017.04.011","article-title":"Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications","volume":"43","author":"Goldberg","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.10.016_bib34","series-title":"Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer","author":"Groen","year":"2021"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321007654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321007654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:41:39Z","timestamp":1760060499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798321007654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0748798321007654"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2021.10.016","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2021.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}